文献速递烧伤创面修复

布比卡因缓释大豆蛋白敷料在大鼠烧伤模型中的镇痛效果研究

In vivo study of the efficacy of bupivacaine-eluting novel soy protein wound dressings in a rat burn model.
PubMed 文献 · Burns · 2021-07-17

本研究开发了一种双层大豆蛋白基 wound dressing,用于局部控释布比卡因,并在大鼠二度烧伤模型中评估其镇痛效果。体外释放显示初始1小时爆发释放61.8±1.9%,随后释放减缓;动物实验表明布比卡因组RGS评分显著低于未处理组,烧伤后1-3天疼痛水平降低51-68%,成功减轻自发性与机械诱导性疼痛至少三天。

要点

  • 双层大豆蛋白敷料可实现布比卡因局部控释,初始1小时释放61.8±1.9%。
  • 在大鼠二度烧伤模型中,布比卡因敷料组烧伤后1-3天RGS评分显著低于未处理组。
  • 疼痛水平降低51-68%,自发性与机械诱导性疼痛均得到缓解,效果至少持续三天。

核心结论

  • 新型布比卡因缓释大豆蛋白敷料在大鼠烧伤模型中成功减轻自发性与机械诱导性疼痛至少三天,是局部控释镇痛的有前景新概念。

研究设计与样本

  • 研究开发双层大豆蛋白基敷料,体外评估布比卡因释放曲线,并在大鼠二度烧伤模型中体内评估疼痛水平。
  • 采用大鼠面部表情量表(RGS)和Von Frey纤维法分别量化自发性疼痛和机械诱导性疼痛。

主要发现

  • 体外释放显示初始1小时爆发释放61.8±1.9%的负载药物,随后一天内释放速率减慢。
  • 动物实验显示布比卡因处理组RGS评分显著低于未处理组,烧伤后1-3天疼痛水平降低51-68%。
  • 成功减轻自发性疼痛和机械诱导性疼痛至少三天。

临床怎么用

  • 该敷料可能为烧伤创面提供局部持续镇痛,减少全身镇痛药使用及相关副作用。
  • 需进一步临床研究验证其在人体烧伤患者中的镇痛效果和安全性。

局限性

  • 研究仅在大鼠二度烧伤模型中进行,结果外推到人类需谨慎。
  • 原文未报告样本量、具体P值等统计细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Dealing with wound related pain is an integral part of treatment. Systemic administration of analgesic and anesthetic agents is a common solution for providing pain relief to patients but comes at a risk of severe side effects as well as addiction. To overcome these issues, research efforts were madeto provide a platform for local controlled release of pain killers. We have developed a bilayer soy protein-based wound dressing for the controlled local release of bupivacaine to the wound site. The combination of a dense and a porous layer provides a platform for cell growth and proliferation as well as physical protection to the wound site. The current study focuses on the in vitro bupivacaine release profile from the dressing and the corresponding in vivo results of pain levels in a second-degree burn model on rats. The Rat Grimace Scale method and the Von Frey filaments method were used to quantify both, spontaneous pain and mechanically induced pain. A high burst release of 61.8 ± 1.9% of the loaded drug was obtained during the initial hour, followed by a slower release rate during the following day. The animal trials show that the RGS scores of the bupivacaine-treated group were significantly lower than these of the untreated group, proving a decrease of 51-68% in pain levels during days 1-3 after burn. Hence, successful pain reduction of spontaneous pain as well as mechanically induced pain, for at least three days after burn was achieved. It is concluded that our novel bupivacaine eluting soy protein wound dressings are a promising new concept in the field of local controlled drug release for pain management.

来源:Burns,查看原文。版权归原作者所有。

引用

  1. Goder D, Eshkol-Yogev I, Matsliah L, et al. In vivo study of the efficacy of bupivacaine-eluting novel soy protein wound dressings in a rat burn model. Burns. 2021. PMID: 34330581. doi:10.1016/j.burns.2021.07.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。